RxDoctor Payments Data

Glenn Davison, MD

Cardiovascular Disease · Chesterfield, MONPI 1518924513

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $89,840 of the $118,424 with a category attached, or 75.9%. 46 manufacturers reported payments, led by Amarin Pharma, Inc. at 51.9% of the total. Reporting peaked in 2019 at $50,409 and has fallen 91.2% since, to $4,411 in 2025. Among cardiovascular disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$118,424in general payments, 2019–2025

Across 673 payments — averaging $175.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$61K
  • Esperion Therapeutics, Inc.$39K
  • Medicure Pharma Inc.$8K
  • Boston Scientific$1K
  • Novartis$1K
  • Pfizer$797
  • plus $7K from 40 others

What the payments were for

  • Consulting fees$7501%
  • Speaking & faculty fees$89,84076%
  • Travel & lodging$14,29212%
  • Food & beverage$13,51511%
  • Education$270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$118,424 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$191,730
Medicare patients
3,621
Services billed
6,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban457$513,593
XareltoRivaroxaban165$184,688
EntrestoSacubitril/Valsartan87$88,229
Repatha SureclickEvolocumab72$80,282
BrilintaTicagrelor44$45,455
VascepaIcosapent Ethyl68$39,619
MultaqDronedarone Hcl25$32,274
NexlizetBempedoic Acid/Ezetimibe34$31,710
Praluent PenAlirocumab48$29,619
Dabigatran EtexilateDabigatran Etexilate Mesylate86$28,226
NexletolBempedoic Acid24$20,340
LivaloPitavastatin Calcium21$11,389
Ezetimibe489$8,394
Nebivolol Hcl108$7,620
Ranolazine ErRanolazine71$6,855

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$797$513,593457 claims
Johnson & JohnsonXarelto$777$184,688165 claims
NovartisEntresto$1,051$88,22987 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$39,259$52,05058 claims
AstraZenecaBrilinta$379$45,45544 claims
Sanofi-aventis U.S. LLCMultaq$357$32,27425 claims
Kowa Pharmaceuticals America, Inc.Livalo$106$11,38921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →